La resistencia antimicrobiana requiere desarrollar innovación tanto en el diagnóstico como en el tratamiento. Se necesitan técnicas de diagnóstico rápido para detección de patógenos resistentes, tanto en el ámbito sanitario como veterinario y ambiental (Estrategia One Health). Por otro lado, se requieren nuevos tratamientos frente a dichas bacterias. Una de las líneas más esperanzadoras es la fagoterapia, por su amplio campo de estudio. Los fagos son virus que lisan las bacterias y que podrían potenciar el uso de los antimicrobianos. Su interés radica en la posibilidad para utilizar fagos naturales o ambientales, así como diseñados por ingeniería e incluso proteínas derivadas de los mismos como lisinas y/o depolimerasas con actividad frente a las bacterias. Finalmente, el conocimiento de los mecanismos bacterianos asociados a la superviviencia de las bacterias ante condiciones de estrés como mecanismos moleculares de tolerancia y/o persistencia bacteriana, son claves para la lucha frente las resistencias antimicrobianas.

Por todo ello, nuestras líneas de investigación son:

• Desarrollo de técnicas moleculares innovadoras ultrarrápidas para el diagnóstico microbiológico con carácter de patentabilidad.
• Estudio de terapias innovadoras frente a bacterias resistentes a los antimicrobianos: FAGOTERAPIA y TERAPIAS ANTIVIRULENTAS.
• Análisis de mecanismos moleculares de persistencia y tolerancia bacteriana.

Número total de publicaciones en revistas científicas relevantes: 115
Número total de publicaciones revistas científicas relevantes en los últimos 5 años: 55 
Factor de impacto global en los últimos 5 años: 250
H-index: 40; i10-index: 70

Selección de los últimos 3 años:

• Bleriot I, Blasco L, Pacios O, et al, Tomás M (12/12). 2023. Proteomic Study of the Interactions between Phages and the Bacterial Host Klebsiella pneumoniae. Microbiol Spectr. 2023. https://journals.asm.org/doi/epub/10.1128/spectrum.03974-22 FACTOR DE IMPACTO: 9,043
• Blasco L, de Aledo MG, Ortiz-Cartagena C, et al, Tomás M (11/!1).2023. Study of 32 new phage tail-like bacteriocins (pyocins) from a clinical collection of Pseudomonas aeruginosa and of their potential use as typing markers and antimicrobial agents. Sci Rep. 2023 Jan 3;13(1):117. https://www.nature.com/articles/s41598-022-27341-1 FACTOR DE IMPACTO: 4,996
• Blasco L, López-Hernández I, Rodríguez-Fernández M, et al. Tomás M, López Cortés LE (11/11). 2023. Case report: Analysis of phage therapy failure in a patient with a Pseudomonas aeruginosa prosthetic vascular graft infection. Front Med (Lausanne). https://www.frontiersin.org/articles/10.3389/fmed.2023.1199657/full FACTOR DE IMPACTO: 5,058
• Bleriot, I.; Blasco, L.; Pacios, O.; et al; Tomás, M. (AC). (14/14). 2022. The role of PemIK (PemK/PemI) type II TA system from Klebsiella pneumoniae clinical strains in lytic phage infection Scientific Report. Springer Nature. https://doi.org/10.1038/s41598-022-08111-5 FACTOR DE IMPACTO: 4,996
• Muthami JM, Fernández-García L, Tomás M, Wood TK. (3/4). 2022. What is the fate of the biofilm matrix? Environ Microbiol. (https://ami-journals.onlinelibrary.wiley.com/doi/10.1111/1462-2920.16097) FACTOR DE IMPACTO: 4,720
• Fernández-García L, Muthami JM, Tomas M, Wood TK. (3/4) 2022. What are the options for treating infections by persister-forming pathogens? Environ Microbiol. (https://ami-journals.onlinelibrary.wiley.com/doi/10.1111/1462-2920.16117) FACTOR DE IMPACTO: 4,720
• Ortiz-Cartagena C, Fernández-García L, Blasco L, Pacios O, Bleriot I, López M, Cantón R, Tomás M (8/8). 2022. Reverse Transcription-Loop-Mediated Isothermal Amplification-CRISPR-Cas13a Technology as a Promising Diagnostic Tool for SARS- CoV-2. Microbiol Spectr. (https://journals.asm.org/doi/epub/10.1128/spectrum.02398-22) FACTOR DE IMPACTO: 9,043
• Pacios, O.; Fernández-García, L.; Bleriot, I.; et al; Tomas, M. (AC). (13/13). 2022. Adaptation of clinical isolates of Klebsiella pneumoniae to the combination of niclosamide with the efflux pump inhibitor phenylarginine-β-naphthylamide (PaβN):co-resistance to antimicrobials Journal of Antimicrobial Chemotherapy. Oxford.. https://doi.org/10.1093/jac/dkac044 FACTOR DE IMPACTO: 5,578
• Lopez-Diaz, M.; Ellaby, N.; Turton, J.; Woodford, N.; Tomas, M. (AC); Ellington, M. J. (5/6). 2022. NDM-1 carbapenemase resistance gene vehicles emergent on distinct plasmid backbones from the IncL/M family. Last author Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkab466 FACTOR DE IMPACTO: 5,578
• Ambroa, A.; Blasco, L.; López, M.; et al; Tomás, M. (AC). (10/10). 2022. Genomic analysis of molecular bacterial mechanisms of resistance to phage infection Frontiers in Microbiology. Frontiers. https://doi.org/10.3389/fmicb.2021.784949 FACTOR DE IMPACTO: 6,064
• Blasco, L.; Bleriot, I.; González de Aledo, M.; et al; Tomás, M. (AC). (14/14). 2022. Development of an anti-Acinetobacter baumannii biofilm phage cocktail:Genomic Adaptation to the Host Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01923-21 FACTOR DE IMPACTO: 5,938
• Pacios, O.; Fernandez-Garcia, L.; Bleriot, I.; et al; Tomas, M. (AC). (13/13). 2021. Phenotypic and Genomic Comparison of Klebsiella pneumoniae Lytic Phages:vB_KpnM-VAC66 and vB_KpnM-VAC13. Viruses. https://doi.org/10.3390/v14010006 FACTOR DE IMPACTO: 5,818
• Pacios, O.; Fernández-García, L.; Bleriot, I.; et al; Tomás, M. (AC). (13/13). 2021. Enhanced antibacterial activity of repurposed mitomycin C and imipenem in combination with the lytic phage vB_KpnM-VAC13 against clinical isolates of Klebsiella pneumoniae Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.00900-21 FACTOR DE IMPACTO: 5,938
• González de Aledo, M.; González-Bardanca, M.; Blasco, L.; et al; Tomás, M. (AC). (10/10). 2021. CRISPR-Cas, a Revolution in the Treatment and Study of ESKAPE Infections: Pre-Clinical Studies Antibiotics (Basel). 10-7. https://doi.org/10.3390/antibiotics10070756 FACTOR DE IMPACTO: 4, 639
• Garcia-Contreras, R.; Tomas, M. (AC). (2/2). 2021. Editorial: Molecular Mechanisms of Bacterial Clinical Pathogens Tolerance and Persistence Under Stress Conditions: Tolerant and Persister Cells Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2021.705092 FACTOR DE IMPACTO: 6,064
• Tuttobene, M. R.; Müller, G. L.; Blasco, L.; et al; Tomás, M. (AC); Mussi, M. A.(8/10). 2021. Blue light directly modulates the quorum network in the human pathogen Acinetobacter baumannii Scientific Report. Springer Nature. 11-1, pp.13375-13375. https://doi.org/10.1038/s41598-021-92845-1 FACTOR DE IMPACTO: 4,996
• Hamidian, M.; Blasco, L.; Tillman, L. N.; To, J.; Tomas, M. (AC); Myers,G. S. A.(5/6). 2020. Analysis of Complete Genome Sequence of Acinetobacter baumannii Strain ATCC 19606 Reveals Novel Mobile Genetic Elements and Novel Prophage Microorganisms. 8-12. https://doi.org/10.3390/microorganisms8121851 FACTOR DE IMPACTO: 4,030
• Fernandez-Garcia, L.; Pacios, O.; González-Bardanca, M.; et al; Tomas, M. (AC). (9/9). 2020. Viral related tools against SARS-CoV-2 Viruses. https://doi.org/10.3390/v12101172 FACTOR DE IMPACTO: 4,980
• Ambroa, A.; Blasco, L.; López-Causapé, C.; et al; Tomás, M. (AC). (14/14). 2020. Temperate Bacteriophages (Prophages) in Pseudomonas aeruginosa Isolates Belonging to the International Cystic Fibrosis Clone (CC274) Frontiers in Microbiology. 11, pp.556706-556706. https://doi.org/10.3389/fmicb.2020.556706 FACTOR DE IMPACTO: 5,640
• Bleriot, I.; Blasco, L.; Delgado-Valverde, M.; et al; Tomas, M. (AC). (13/13). 2020. Mechanisms of Tolerance and Resistance to Chlorhexidine in Clinical Strains of Klebsiella pneumoniae Producers of Carbapenemase: Role of New Type II Toxin-Antitoxin System, PemIK Toxins (Basel). 12-9. https://doi.org/10.3390/toxins12090566 FACTOR DE IMPACTO: 5,456
• Bleriot, I.; Trastoy, R.; Blasco, L.; et al; Tomas, M. (AC). (16/16). 2020. Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae Microb Genom. 6-5. https://doi.org/10.1099/mgen.0.000369  FACTOR DE IMPACTO: 5,348
• Pacios, O.; Blasco, L.; Bleriot, I.; et al; Tomas, M. (AC). (9/9). 2020. Strategies to Combat Multidrug-Resistant and Persistent Infectious Diseases Antibiotics (Basel). 9-2. https://doi.org/10.3390/antibiotics9020065 FACTOR DE IMPACTO: 4,930
• Blasco, L.; Ambroa, A.; Trastoy, R.; et al; Tomas, M. (AC). (19/19). 2020. In vitro and in vivo efficacy of combinations of colistin and different endolysins against clinical strains of multi-drug resistant pathogens Scientific Report. Springer Nature. 10-1, pp.7163-7163. https://doi.org/10.1038/s41598-020-64145-7 FACTOR DE IMPACTO: 4,996
• Pacios, O.; Blasco, L.; Bleriot, I.; et al; Tomas, M. (AC). (11/11). 2020. (p)ppGpp and its role in bacterial persistence: New challenges Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.01283-20 FACTOR DE IMPACTO: 5,938
• Fernandez-Garcia, L.; Kim, J. S.; Tomas, M.; Wood, T. K. (3/4). 2019. Toxins of toxin/antitoxin systems are inactivated primarily through promoter mutations J Appl Microbiol. 127-6, pp.1859-1868. https://doi.org/10.1111/jam.14414 FACTOR DE IMPACTO: 4,720
• L. Blasco; A. Ambroa; M. Lopez; et al; M. Tomas (AC). (17/17). 2019. Combined Use of the Ab105-2phiDeltaCI Lytic Mutant Phage and Different Antibiotics in Clinical Isolates of Multi-Resistant Acinetobacter baumannii Microorganisms. 7-11. https://doi.org/10.3390/microorganisms7110556 FACTOR DE IMPACTO: 4,830
• M.R. Tuttobene; L. Fernandez-Garcia; L. Blasco; et al; Mussi, M. A. (AC). (16/16). 2019. Quorum and Light Signals Modulate Acetoin/Butanediol Catabolism in Acinetobacter app Front Microbiol. 10, pp.1376-1376. https://doi.org/10.3389/fmicb.2019.01376 FACTOR DE IMPACTO: 4,235
• R.T. Pena; L. Blasco; A. Ambroa; et al; M. Tomas (AC). (11/11). 2019. Relationship Between Quorum Sensing and Secretion Systems Front Microbiol. 10, pp.1100-1100. https://doi.org/10.3389/fmicb.2019.01100 FACTOR DE IMPACTO: 4,235
• Fernández-García, L.; Blasco, L.; Ambroa, A.; et al; M.Tomas (AC). (13/13). 2019. Quorum and Light Signals Modulate Acetoin/Butanediol Catabolism in Acinetobacter spp Front Microbiol. Frontiers. https://doi.org/10.3389/fmicb.2019.01376 FACTOR DE IMPACTO: 4,235
• Fernandez-Cuenca, F.; Tomas, M.; Tormo, M.; Gimeno, G; Bou, G; Pascual, A.(2/6). 2019. Reporting identification of Acinetobacter spp genomic species: A nationwide proficiency study in Spain Enfermedades Infecciosas y Microbiología Clinica. Elservier. 37-2. https://doi.org/10.1016/j.eimc.2018.02.004 FACTOR DE IMPACTO: 1,994
• Wood, TK.; Garcia-Contreras, R.; Tomas, M. (AC). (3/3). 2019. Quorum Network (Sensing/Quenching) in Multidrug-Resistant Pathogens. April. Front Microbiol. https://doi.org/10.3389/fcimb.2019.00080 FACTOR DE IMPACTO: 4,235
• Alcaide, F.; Moure, R.; Trastoy, R.; et al; Tomas, M. (AC). (11/11). 2019. Multiplex Real time PCR-shortTUB assay for detection of the Mycobacterium tuberculosis complex in smear-negative extrapulmonary clinical samples J Clin Microb. American Society Microbiology. https://doi.org/10.1128/JCM.00733-19 FACTOR DE IMPACTO: 5,948